The impact of ageing mechanisms on musculoskeletal system diseases in the elderly

Yijin Cai, Zhongyu Han, Hong Cheng, Hongpeng Li, Ke Wang, Jia Chen, Zhixiang Liu, Yu‐Long Xie, Yumeng Lin, Shuwei Zhou, Siyu Wang, Xiao‐Hua Zhou, Song JinFrontiers in Immunology 2024 · DOI

This review paper, published in Frontiers in Immunology (May 2024), provides a comprehensive synthesis of how fundamental biological aging mechanisms drive the progression of musculoskeletal system diseases.

TL;DR

This paper maps the "hallmarks of aging"—such as cellular senescence, telomere attrition, and mitochondrial dysfunction—directly to the pathogenesis of osteoarthritis, osteoporosis, and sarcopenia. It argues that the future of geriatric medicine lies in "senotherapies" that target these root molecular causes rather than just managing the symptoms of physical decline.

What Problem Does This Paper Address?

As the global population ages, musculoskeletal diseases (MSDs) have become the leading cause of chronic pain and disability. Traditionally, diseases like osteoarthritis (OA) or osteoporosis (OP) were viewed as "wear and tear" or simple mineral loss. However, clinical interventions often arrive too late, focusing on symptom management (like joint replacements or pain relief) rather than prevention.

The authors address the need for a unified biological framework that explains why these tissues fail. By connecting the dots between basic geroscience (the study of aging biology) and clinical orthopedics, the paper identifies specific molecular targets that could lead to "disease-modifying" rather than just "symptom-modifying" treatments.

Methods

As a Review Article, this paper does not present a single new experiment. Instead, it synthesizes findings from 205 peer-reviewed studies. The authors categorize the complex process of aging into 11 distinct but interrelated mechanisms:

  1. Cellular Senescence: The accumulation of "zombie cells" that stop dividing but remain metabolically active.
  2. SASP (Senescence-Associated Secretory Phenotype): The pro-inflammatory cocktail secreted by senescent cells.
  3. Telomere Attrition: The shortening of chromosomal caps.
  4. Epigenetic Changes & Genomic Instability: Damage to the "software" and "hardware" of the cell.
  5. Mitochondrial Dysfunction: Power plant failure leading to oxidative stress.
  6. Loss of Proteostasis: The buildup of misfolded proteins.
  7. Nutrient Sensing, Stem Cell Exhaustion, and Macroautophagy Disruption.

The paper then maps these mechanisms specifically onto the pathology of the bone (osteoporosis), cartilage (osteoarthritis), and muscle (sarcopenia).

Datasets

Not discussed in the paper. (This is a literature review and does not introduce new datasets or benchmarks.)

Key Insights and Ideas

  • The "Malignant Cycle" of SASP: One of the most critical insights is that senescent cells don't just sit idle. Through SASP, they secrete cytokines (like IL-6 and TNF-α) and proteases (like MMPs) that "poison" the local microenvironment. This turns healthy neighboring cells senescent, creating a self-propagating wave of tissue degradation.
  • Inflammaging & "Molecular Junk": The paper highlights "inflammaging"—chronic, low-grade inflammation driven by the body's inability to clear cellular debris. For example, leaking mitochondrial DNA (mtDNA) acts as a "danger signal" (DAMP), triggering innate immune pathways (cGAS/STING) that lead to bone loss.
  • Stem Cell Fate Shifting: In osteoporosis, aging causes Mesenchymal Stem Cells (MSCs) to shift their differentiation. Instead of becoming bone-building osteoblasts, they are "tricked" into becoming adipocytes (fat cells), leading to fatty bone marrow and structural weakness.
  • Senolytics vs. Senomorphics: The authors distinguish between two therapeutic strategies:
  • Senolytics: Drugs (like Navitoclax or Quercetin + Dasatinib) that selectively kill senescent cells.
  • Senomorphics: Drugs (like Rapamycin/mTOR inhibitors) that don't kill the cells but suppress their harmful secretions (SASP).

Key Results

The paper summarizes the specific molecular drivers for the "Big Three" musculoskeletal conditions:

  • Osteoarthritis: Driven by chondrocyte senescence and the upregulation of MMP-13, which literally "cuts" the type II collagen in cartilage.
  • Osteoporosis: Driven by an imbalance where osteoclast (bone-dissolving) activity outpaces osteoblast (bone-building) activity, fueled by SASP factors like RANKL.
  • Sarcopenia: Characterized by the loss of muscle satellite cells (stem cells) and a decline in IGF-1 signaling, which is essential for muscle protein synthesis.

Qualitatively, the review notes that in animal models, clearing senescent cells via senolytics has successfully improved bone microarchitecture and increased muscle strength, suggesting high translational potential.

Limitations and Future Work

  • Animal-to-Human Gap: Most of the "breakthrough" results cited (such as the use of UBX0101 for OA) are based on mouse models. Human clinical trials are still in their infancy and have faced hurdles regarding efficacy and timing.
  • The "Timing" Problem: Senescence actually plays a positive role in wound healing and tumor suppression in younger organisms. Determining when to intervene without disrupting these essential functions remains a major challenge.
  • Biomarker Scarcity: There is currently no "gold standard" biomarker to easily quantify the "senescent load" in a living human patient's joints or muscles, making it difficult to tailor treatments.
  • Future Direction: The authors call for more research into the "interplay" between these mechanisms—how telomere loss triggers mitochondrial failure, which in turn triggers SASP—to find the most effective "master switch" for intervention.

Summary updated

Abstract

Ageing is an inevitable process that affects various tissues and organs of the human body, leading to a series of physiological and pathological changes. Mechanisms such as telomere depletion, stem cell depletion, macrophage dysfunction, and cellular senescence gradually manifest in the body, significantly increasing the incidence of diseases in elderly individuals. These mechanisms interact with each other, profoundly impacting the quality of life of older adults. As the ageing population continues to grow, the burden on the public health system is expected to intensify. Globally, the prevalence of musculoskeletal system diseases in elderly individuals is increasing, resulting in reduced limb mobility and prolonged suffering. This review aims to elucidate the mechanisms of ageing and their interplay while exploring their impact on diseases such as osteoarthritis, osteoporosis, and sarcopenia. By delving into the mechanisms of ageing, further research can be conducted to prevent and mitigate its effects, with the ultimate goal of alleviating the suffering of elderly patients in the future.
BibTeX
@inproceedings{cai2024impact,
  author = {Yijin Cai and Zhongyu Han and Hong Cheng and Hongpeng Li and Ke Wang and Jia Chen and Zhixiang Liu and Yu‐Long Xie and Yumeng Lin and Shuwei Zhou and Siyu Wang and Xiao‐Hua Zhou and Song Jin},
  title = {{The impact of ageing mechanisms on musculoskeletal system diseases in the elderly}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1405621},
}
Figure